JD Supra15d
FDA Accepts BLA for Shanghai Henlius Biotech’s HLX11, a Pertuzumab Biosimilar
On February 2, 2025, Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for HLX11, a proposed biosimilar to Genentech’s PERJETA.
C&EN19d
Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective
Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland ...
rnz23d
Pharmac reconsiders decision on HRT oestrogen patches
Pharmac is reconsidering its decision to fund only one brand of HRT oestrogen patches after receiving considerable feedback. The patches are used by menopausal people as a hormone replacement therapy ...
ascopubs.org29d
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study
blockade with trastuzumab and pertuzumab with the current standard of care, taxane plus trastuzumab and pertuzumab, in HER2-positive metastatic breast cancer (MBC). Compared with the taxane-based ...